Medindia

X

Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring

Friday, November 30, 2007 General News J E 4
Advertisement
UPPSALA, Sweden, November 30 Cavidi AB, a producer ofmedical diagnostic products, today announced an agreement with the ClintonFoundation HIV/AIDS Initiative (CHAI). Under the agreement, Cavidi'sExaVir(TM) Load assay will be immediately available to members of CHAI'sProcurement Consortium at a discounted price. With more than 70 developingcountries in the consortium, the agreement is a significant step in makingviral load monitoring more accessible to HIV-positive patients in thedeveloping world.

Viral load monitoring is essential for the proper management ofHIV-positive patients being treated with antiretroviral drugs (ARVs). Thetest helps doctors use ARVs more effectively to extend a patient's length andquality of life, limit the development of viral resistance and minimize wasteof medication. "Viral load testing is an essential part of HIV management. Asmore people in the developing world gain access to ARVs, it's important thataccess to viral load testing keeps pace," said Cavidi CEO Martyn Eales. "It'sCavidi's goal to make monitoring more accessible in all countries. I'm verypleased with our partnership with President Clinton's Foundation because itbrings us closer to reaching that goal."

Although viral load monitoring has been a standard part of treatment indeveloped countries, it has been considered impractical for use in developingnations where HIV infection is most widespread. That is because traditionalviral load tests are expensive and require technically advanced laboratoryfacilities. ExaVir Load is the first HIV viral load test designed to overcomethese obstacles. Several independent studies have shown the assay to be asaccurate and reliable as any other commercially available test, with theadded benefit of being able to detect all known subtypes of HIV. This isparticularly important in regions like sub-Saharan Africa where different HIVsubtypes are common.

"We face a global HIV/AIDS emergency and laboratory tests are a vitalcomponent of HIV/AIDS care and treatment," said Deepak Verma, CEO of CHAI."The success of treatment programs is dependent not only on the ability todiagnose and qualify HIV-positive patients for therapy, but also to monitortreatment efficacy and safety and to manage disease treatment. We are pleasedto work with Cavidi and commend them for helping to make HIV viral load testsavailable at lower cost to members of our Procurement Consortium."

About Cavidi AB

Cavidi AB was founded by leading virologists at Uppsala University inSweden in 1984. The company's mission is to make medical diagnostics moreaccessible in those parts of the world where resources and infrastructure arelimited. Their products include ExaVir Load and ExaVir Drug, which are usedin HIV management. For press photos and more information, please visit,http://www.cavidi.com

About Clinton Foundation HIV/AIDS Initiative (CHAI)

Since 2002, CHAI has been assisting countries in implementinglarge-scale, integrated HIV/AIDS care and treatment programs. It partnerswith 28 countries in Africa, the Caribbean and Asia. Individual governmentstake the lead and CHAI provides technical assistance, mobilizes human andfinancial resources, and facilitates the sharing of best practices acrossprojects. CHAI also provides access to reduced prices for HIV/AIDS drugs anddiagnostics to more than 70 countries.For more information, please visit: http://www.clintonfoundation.org For further information and interview requests please contact: Kajsa Lowenhielm Information Manager, Cavidi AB Mobile: +46-709-42-90-50 kajsa@cavidi.se

SOURCE Cavidi AB
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Actress Colleen Zenk Pinter Partners with the Oral...
S
Cell Therapeutics, Inc. Announces $6.5 Million Off...